Check for updates

OPEN ACCESS

EDITED BY Yinong Huang, Sun Yat-sen University, China

REVIEWED BY Raffaele Ornello, University of L'Aquila, Italy Hipólito Nzwalo, University of Algarve, Portugal

*CORRESPONDENCE Guang-Qin Li ⊠ liguangqin@tom.com

SPECIALTY SECTION This article was submitted to Stroke, a section of the journal Frontiers in Neurology

RECEIVED 20 November 2022 ACCEPTED 07 February 2023 PUBLISHED 03 March 2023

CITATION

Tang Y, Liu M-S, Fu C and Li G-Q (2023) Sex-dependent association analysis between serum uric acid and spontaneous hemorrhagic transformation in patients with ischemic stroke. *Front. Neurol.* 14:1103270. doi: 10.3389/fneur.2023.1103270

COPYRIGHT

© 2023 Tang, Liu, Fu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Sex-dependent association analysis between serum uric acid and spontaneous hemorrhagic transformation in patients with ischemic stroke

Ye Tang, Ming-Su Liu, Chong Fu and Guang-Qin Li*

Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Objective: The association between serum uric acid (UA) and spontaneous hemorrhagic transformation (HT) has been seldom studied, and the role of UA in spontaneous HT remains unclear. This study aims to investigate the sex-dependent association between UA and spontaneous HT in patients with ischemic stroke.

Method: We retrospectively included patients with ischemic stroke in a tertiary academic hospital between December 2016 and May 2020. Patients were included if they presented within 24 h after the onset of symptoms and did not receive reperfusion therapy. Spontaneous HT was determined by an independent evaluation of neuroimaging by three trained neurologists who were blinded to clinical data. A univariate analysis was performed to identify factors related to spontaneous HT. Four logistic regression models were established to adjust each factor and assess the association between UA and spontaneous HT.

Results: A total of 769 patients were enrolled (64.6% were male patients and 3.9% had HT). After adjusting the confounders with a P < 0.05 (model A) in the univariate analysis, the ratio of UA and its interquartile range (RUI) was independently associated with spontaneous HT in male patients (OR: 1.85; 95% CI: 1.07–3.19; P = 0.028), but not in female patients (OR: 1.39; 95% CI: 0.28–6.82; P = 0.685). In models B–D, the results remain consistent with model A after the adjustment for other potential confounders.

Conclusions: Higher serum UA was independently associated with a higher occurrence of spontaneous HT in male patients who were admitted within 24 h after the stroke onset without receiving reperfusion therapy.

KEYWORDS

uric acid, hemorrhagic transformation, reperfusion therapy, admission time, male

Introduction

Spontaneous hemorrhagic transformation (HT) is defined as the blood stain of an infarcted cerebral area formed by the overflow of red blood cells and other blood components from blood vessels to the infarcted brain tissue, which is a part of the natural course of ischemic stroke and a crucial complication of treatment (1). Spontaneous HT occurs in \sim 13–43% of patients with ischemic stroke, and parenchymal hematoma is a critical factor in poor outcomes (2). Thus, it is important to identify the factors that determine the occurrence of HT. However, the pathophysiological mechanism of spontaneous HT remains uncertain.

Uric acid (UA) is an endogenous antioxidant produced by purine metabolism (3, 4). If the antioxidant substances are abundant, UA will show antioxidant properties. If there are more pro-oxidant substances, it will show pro-oxidant properties (5). In patients with acute ischemic stroke, oxygen free radicals will be produced after tissue ischemia-reperfusion, and UA presents antioxidant or pro-oxidant properties depending on the surrounding substances. It has been demonstrated that the doseresponse relationship between UA and HT and higher UA was independently associated with a lower incidence of HT. On the contrary, higher UA levels are reported to be associated with a lower incidence of HT in different settings (6). An examination of UA is widely available in almost all clinical settings. For these reasons, UA may be a protective factor for spontaneous HT. Therefore, the critical clinical significance of the relationship between UA and spontaneous HT is a topic of research interest.

Nevertheless, reperfusion and blood-brain injury barrier damage after infarction are considered the two major causes of spontaneous HT, and the reactive oxygen species (ROS)-mediated oxidative stress response has an important role in these two mechanisms (7). Many studies have explored the role of thrombolysis in HT occurrence (1, 7, 8). Although thrombectomy is not independently associated with spontaneous HT (9), given its mechanism of reperfusion therapy (e.g., thrombolysis or thrombectomy), the restoration of blood flow to the salvageable ischemic brain tissue is consistent with the aforementioned mechanism of spontaneous HT and the high incidence of spontaneous HT found by previous studies (10-12). None of these prior studies assessed spontaneous HT with respect to non-reperfusion strategies.

There is no consensus on the association between UA and spontaneous HT in patients with acute ischemic stroke. Studies of the relationship between UA levels and spontaneous HT are contradictory. Positive and negative in the male population or both positive in men and women have been described (8, 10, 13, 14). Furthermore, Brouns et al. found that UA changed with time in patients with stroke and exhibited a U-shaped curve in general, which decreased within 7 days after the stroke onset and then gradually increased to the baseline value (15). Few studies have explored the impact of UA levels in specific stroke subtypes and treatment strategies in the acute stage. UA levels are sex-dependent and are higher in males. Therefore, a sexdependent explorative analysis was made using patients with acute ischemic stroke within 24 h after the stroke onset and who did not receive reperfusion therapy (thrombolysis or thrombectomy) after the onset to investigate whether UA was associated with spontaneous HT.

Methods

Population

We retrospectively reviewed the medical records of patients with ischemic stroke admitted to the Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, from December 2016 to May 2020. For this analysis, the patients were included if they: (1) met the diagnostic criteria of acute ischemic stroke (AIS) in the Guidelines for Early Management of Patients With Acute Ischemic Stroke (2019) of the American Heart Association (AHA) (14), (2) were admitted within 24 h from the onset, (3) completed a serum UA test within 24 h after admission, and (4) had an initial neuroimaging scan [computed tomography (CT) scanning or magnetic resonance imaging (MRI)] within 24 h after admission and at least one follow-up neuroimaging scan within 7 days after admission. The exclusion criteria were as follows: (1) patients who received reperfusion therapy (thrombolysis or thrombectomy) after the onset, (2) patients with platelet abnormalities or coagulation dysfunction, (3) patients who received UA-lowering treatment within 1 month before admission, and (4) patients with intracranial arteriovenous malformation or tumor or head trauma. The First Affiliated Hospital of Chongqing Medical University Institutional Review Board approved this study. Written informed consent was obtained from participants or their legal representatives.

Data collection

The clinical data were collected from each patient by two researchers: (1) demographic characteristics, such as age and sex; (2) medical histories, such as the history of smoking, alcohol consumption, hypertension, diabetes, dyslipidemia, and atrial fibrillation (AF); (3) clinical variables, such as National Institute of Health Stroke Scale (NIHSS), the Trial of ORG 10172 in Acute Stroke classification (TOAST), systolic blood pressure (SBP), diastolic blood pressure (DBP), and time from the stroke onset to admission; (4) laboratory tests, such as platelet count, activated partial thromboplastin time, serum UA, estimated glomerular filtration rate (eGFR), serum creatinine, lowdensity lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c); (5) radiological characteristics, such as large hemispheric infarction (LHI) and spontaneous HT; and (6) treatment, such as anticoagulants, antiplatelet drugs, antihypertensive drugs, and antidiabetic drugs. Among them, eGFR was calculated by the serum creatinine level according to the formula of the Chronic Kidney Disease Epidemiology Collaboration (16). The cerebral infarct, of size >2/3 of MCA territory, was defined as LHI (17).

Serum UA concentration was tested by the enzymatic method (Roche Cobas C701) or the dry chemistry method (Ortho-Clinical Diagnostics). The diagnosis of spontaneous HT is based on the following criteria: abnormal hyperdensity within the area of low attenuation (CT) or abnormal hypointensity within the identified ischemic area (MRI) (13). The images were evaluated by two neurologists who were blinded to the patient's information. For inconsistent interpretations, the imaging was independently

Abbreviations: UA, uric acid; IQR, inter-quartile range; RUI, the ratio of UA and its IQR (RUI = UA/IQR); HT, hemorrhagic transformation; R2, R-square of Hosmer–Lemeshow Test; OR, odds ratio; CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke; HbA1c, hemoglobin A1c, eGFR, estimated glomerular filtration rate.



assessed by another senior neurologist, and the final diagnosis was determined on the principle of subordination of the minority to the majority. Furthermore, we classified spontaneous HT into four subtypes [type 1 and 2 hemorrhagic infarction (HI1 and 2) and type 1 and 2 parenchymal hemorrhage (PH1 and 2)] according to the European Cooperative Acute Stroke Study III (ECASS III) (18).

Statistical analysis

Since there is no clinical significance of a 1-unit (1 μ mol/L) change in UA in clinical practice, in this study, the ratio of UA and its interquartile range [RUI, male: RUI = (UA of individual male patient)/(IQR of UA in the male group), female: RUI = (UA of individual female patient)/(IQR of UA in the female group)] was used to replace UA in the statistical analysis, for increasing the practicability of the conclusions in clinical diagnosis and treatment. Continuous variables were expressed as the mean and standard deviation, and categorical variables were expressed as frequency and percentage. The comparison of continuous variables between groups was made by performing the *t*-test or Mann–Whitney Utest, whereas the comparison of categorical variables was made by

performing the chi-square test or Fisher's exact test. In addition, the factors with a P < 0.05 in the univariate analysis and other factors that potentially could affect the study results were included in the subsequent logistic regression analysis. UA levels are lower in female patients, and a sex-dependent association between UA and cardiovascular disease was reported. Therefore, sex-dependent analysis was performed to investigate the impact of UA levels on HT occurrence. In total, four logistic regression models were built, and the association between UA and spontaneous HT was determined by dividing patients into two subgroups of male and female. These variables were chosen based on their known associations with the occurrence of HT, and their demonstrated link to HT in the logistical regression: Model A is adjusted for variables with a P < 0.05 in male (or female) patient subgroup univariate analysis; model B is adjusted for variables with a P <0.05 in both subgroup univariate analysis; model C is adjusted for variables in model B, antiplatelet treatment, and anticoagulant treatment; model D is adjusted for variables in model C, smoking, alcohol consumption, systolic blood pressure, and eGFR. A P <0.05 was considered statistically significant. Data analysis of the present study was performed by using SPSS Statistics Software (version 26.0; IBM Corporation) and GraphPad Prism (version 7.0; GraphPad Software Corporation).

TABLE 1 Baseline characteristics of participants.

DemographicMan age, y (D)6.50.12.87.01.02.0Machal exp (SD)5.10.12.87.01.02.0Machol consumption, n (%)5.10.02.07.01.02.07.01.02.0Mypertension, n (%)5.01.02.07.01.02.07.01.02.0Diabets malitus, n (%)7.01.02.07.01.02.07.01.02.0Mylipidemia, n (%)7.01.02.07.01.02.07.01.02.0Maria fabrillation, n (%)7.01.02.07.01.02.07.01.02.0Mylipidemia, n (%)7.01.02.07.01.02.07.01.02.0Maria fabrillation, n (%)7.01.02.07.01.02.07.01.02.0Mylipidemia, n (%)14.10.501.01.02.07.01.02.0Mylipidemia, n (%)1.01.02.07.01.02.07.01.02.0Mylipidemia, n (%) <th>Variables</th> <th>Male (n = 497)</th> <th>Female (n = 272)</th> <th>P value</th>	Variables	Male (n = 497)	Female (n = 272)	P value					
Medical historyMedical historyAlcohol consumption, n (%)251 (50.5%9 (3.3%)<0.001	Demographic								
Alcohol consumption, n (%)251 (50.5%)9 (3.3%)<.0001Smoking, n (%)353 (71%)13 (4.8%)<.0010	Mean age, y (SD)	65.0 (12.4)	70.3 (12.0)	< 0.001					
Smoking n (%)3533 (71%)13 (4.8%)<.0.001Hypertension, n (%)361 (72.6%)199 (73.2%)0.875Diabetes mellitus, n (%)97 (19.5%)46 (16.9%)0.375Dyslipidemia, n (%)97 (19.5%)46 (16.9%)0.375Atrial fibrillation, n (%)57 (11.5%)47 (17.3%)0.024Clinical features151.8 (23.7)154.0 (24.4)0.375Systolic blood pressure, mmHg (SD)88.3 (16.1)86.4 (14.5)0.103Admission NHSS score, mean (SD)4.6 (5.0)5.0 (4.9)0.037Gmall-artery occlusion191 (38.4%)100 (36.8%)0.049Gradio-embolism53 (10.7%)101 (3.0%)0.623Gurdia-embolism53 (10.7%)103.6%)0.623Other eriology151.8 (23.7)10.370.623Other eriology153 (10.7%)10.13.7%)0.623Other eriology153 (10.7%)10.13.7%)0.623Other eriology153 (10.7%)10.13.7%)0.632Other eriology193.6 (75.8)10.93.60.031Other eriology193.6 (75.8)198.9 (5.7)0.354ApTT, s (SD)261.4(9)25.9 (7.9)0.803Grum CHA, µmol/L (SD)26.1 (4.9)26.1 (4.9)0.101Grum creatinine, µmol/L (SD)26.1 (4.9)3.0 (1.9)0.101Gruft, s (SD)36.1 (1.0)3.0 (1.0)0.101Grum creatinine, µmol/L (SD)26.1 (4.9)3.0 (1.9)0.102Gruft, s (SD)36.1 (1.0)3.0 (1.0)3.0 (1.0)<	Medical history								
Hypertension, n (%)361 (72.6%)199 (73.2%)0.375Diabetes mellitus, n (%)152 (30.6%)43 (30.5%)0.984Dyslipidemia, n (%)7 (11.5%)4 (16.9%)0.375Atrial fibrillation, n (%)57 (11.5%)4 (17.3%)0.024 Clinical features Time from onset to Admission, h (SD)14.1 (8.5)14.0 (8.5)0.584Systolic blood pressure, mmHg (SD)83.3 (16.1)86.4 (14.5)0.103Admission NIHSS score, mean (SD)4.6 (5.0)5.0 (4.9)0.007TAGAST classification, n (%)5.0 (4.9)0.0070.003Gardia-entery atherosclerosis234 (47.1%)101 (40.4%)0.077Small-artery occlusion191 (38.4%)100 (36.8%)0.643Other etiology191 (30.6%)10.13.7%0.623Undetermined etiology193.6 (7.5)10.13.7%0.632Other etiology193.6 (7.5)19.8 (6.7)0.354Platelet count, ±10°/L (SD)19.3 (6.16)19.4 (6.16)0.012Serum UA, µmol/L (SD)32.0 (A.8)27.0 (A.9)0.012Grum eratinine, µmol/L (SD)32.0 (A.9)3.0 (A.9)0.012Gerg, mL/min/1.73 m² (SD)86.1 (2.1)3.0 (A.9)0.132Gurdongical characteristics3.0 (A.9)0.2140.132Gurdongical characteristics3.0 (A.9)0.2140.132Gurdongical characteristics3.0 (A.9)0.2140.224Gurdongical characteristics3.0 (A.9)0.214Gurdongical characteristic	Alcohol consumption, n (%)	251 (50.5%)	9 (3.3%)	< 0.001					
The Diabetes mellitus, n (%)152 (30.6%)83 (30.5%)0.984Dyslipidemia, n (%)97 (19.5%)46 (16.9%)0.375Atrial fibrillation, n (%)57 (11.5%)47 (17.3%)0.024 Clinical features Time from onset to Admission, h (SD)14.1 (8.5)14.0 (8.5)0.584Systolic blood pressure, mmHg (SD)88.3 (16.1)86.4 (14.5)0.103Diastolic blood pressure, mmHg (SD)4.6 (5.0)5.0 (4.9)0.404Admission NIHSS score, mean (SD)4.6 (5.0)5.0 (4.9)0.037TAGAST classification, n (%)101 (34.0%)0.0770.338Small-artery occlusion234 (47.1%)100 (36.8%)0.649Gradio-embolism53 (10.7%)46 (16.9%)0.613Undetermined etiology15 (3.0%)101(3.7%)0.623Other etiology40.8%)62.2%)0.179Platelet count, *10°/L (SD)913.6 (75.8)198.9 (65.7)0.354APTT, s (SD)26.1 (4.9)25.9 (7.9)0.808Serum UA, µmol/L (SD)32 (18.4)10.120.012GeFR, mL/min/L37 m² (SD)86.1 (21.0)82.2 (19.4)0.012HA1c, % (SD)6.8 (1.6)6.8 (1.9)0.516LDL-C, µmol/L (SD)29.1 (1.3)3.0 (1.8)0.128Fyontaneous HT, n (%)18 (3.6%)12 (4.4%)0.589Large hemispheric infarction, n (%)18 (3.6%)12 (4.4%)0.233Gradiogical characteristics12 (4.1%)0.213LDL-C, µmol/L (SD)18 (3.6%) <td>Smoking, n (%)</td> <td>353 (71%)</td> <td>13 (4.8%)</td> <td>< 0.001</td>	Smoking, n (%)	353 (71%)	13 (4.8%)	< 0.001					
Dyslipidemia, n (%)97 (19.5%)46 (16.9%)0.375Atrial fibrillation, n (%)57 (11.5%)47 (17.3%)0.024Clinical featuresTime from onset to Admission, h (SD)14.1 (8.5)14.0 (8.5)0.584Systolic blood pressure, mmHg (SD)88.3 (16.1)86.4 (14.5)0.103Diastolic blood pressure, mmHg (SD)4.6 (5.0)5.0 (4.9)0.404Admission NIHSS score, mean (SD)4.6 (5.0)5.0 (4.9)0.037TOAST classification, n (%)110 (40.4%)0.0770.038Large-artery atherosclerosis234 (47.1%)110 (40.4%)0.613Gradia-embolism53 (10.7%)46 (16.9%)0.613Undetermined etiology15 (3.0%)10 (3.7%)0.623Other etiology40 (8.8%)10 (3.7%)0.623Dysleted count, *10°/L (SD)26.1 (4.9)25.9 (7.9)0.808Serum UA, µmol/L (SD)26.1 (4.9)25.9 (7.9)0.801Grum creatinine, µmol/L (SD)3.2 (0.8)6.2 (2.9)0.013Grum creatinine, µmol/L (SD)86.1 (2.10)82.0 (1.9)0.013Grum creatinine, µmol/L (SD)6.8 (1.6)6.8 (1.9)0.135HAALc, % (SD)2.9 (1.2)3.0 (1.8)0.148Lucy (SD)6.8 (1.6)6.8 (1.9)0.135Grum creatinine, µmol/L (SD)6.8 (1.6)6.8 (1.9)0.135Lucy (SD)6.8 (1.6)6.8 (1.9)0.148Lucy (SD)6.8 (1.6)6.8 (1.9)0.148Lucy (SD)6.8 (1.6)6.8 (1.9)<	Hypertension, <i>n</i> (%)	361 (72.6%)	199 (73.2%)	0.875					
Atrial fbrillation, n (%)57 (11.5%)47 (17.3%)0.024Clinical featuresUtilization on set to Admission, h (SD)14.1 (8.5)14.0 (8.5)0.584Systolic blood pressure, mmHg (SD)88.3 (16.1)86.4 (14.5)0.103Diastolic blood pressure, mmHg (SD)4.6 (5.00)5.0 (4.9)0.404Admission NIHSS score, mean (SD)4.6 (5.00)5.0 (4.9)0.013TOAST classification, n (%)101 (4.04%)0.0770.338Small-artery occlusion234 (47.1%)100 (3.6.8%)0.649Gradio-embolism53 (10.7%)46 (16.9%)0.613Other etiology15 (3.0%)10 (3.7%)0.623Other etiology4 (0.8%)6 (2.2%)0.133Other etiology193.6 (75.8)18.9 (65.7)0.354APTT, s (SD)26.1 (4.9)25.9 (7.9)0.808Serum UA, µmol/L (SD)362.8 (9.6)34.8 (87.9)0.013GFR, mL/min/L3Dm ² , (SD)6.8 (1.6.1)8.6 (1.6.1)0.134GFR, mL/min/L3Dm ² , (SD)6.8 (1.6.1)8.6 (1.6.1)0.148GFR, mL/min/L3Dm ² , (SD)6.8 (1.6.1)3.0 (1.8)0.148Gradeous HT, n (%)18.1 (3.0%)12.1 (4.4%)0.134Large-henispheric infarction, n (%)18.1 (3.0%)12.1 (4.1%)0.148Large-henispheric infarction, n (%)18.1 (3.0%)12.1 (4.1%)0.148Large-henispheric infarction, n (%)18.1 (3.0%)12.1 (4.1%)0.148Large-henispheric infarction, n (%)18.1 (3.1%) <td>Diabetes mellitus, n (%)</td> <td>152 (30.6%)</td> <td>83 (30.5%)</td> <td>0.984</td>	Diabetes mellitus, n (%)	152 (30.6%)	83 (30.5%)	0.984					
Clinical features Filter from onset to Admission, h (SD) 14.1 (8.5) 14.0 (8.5) 0.584 Systolic blood pressure, mmHg (SD) 151.8 (23.7) 154.0 (24.4) 0.233 Diastolic blood pressure, mmHg (SD) 88.3 (16.1) 86.4 (14.5) 0.103 Admission NIHSS score, mean (SD) 4.6 (5.0) 5.0 (4.9) 0.0038 TOAST classification, n (%) 110 (40.4%) 0.007 Small-artery atherosclerosis 234 (47.1%) 110 (40.4%) 0.007 Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Platelet count, ±10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 32.2 (0.8) 6.2 (20.1) 0.012 GFR, mL/min/1.73 m ² , (SD) 86.1 (21.0) 82.2 (19.4) 0.012 GFR, mL/min/L (SD)	Dyslipidemia, n (%)	97 (19.5%)	46 (16.9%)	0.375					
Time from onset to Admission, h (SD)14.1 (8.5)14.0 (8.5)0.584Systolic blood pressure, mmHg (SD)151.8 (23.7)154.0 (24.4)0.233Diastolic blood pressure, mmHg (SD)88.3 (16.1)86.4 (14.5)0.103Admission NIHSS score, mean (SD)4.6 (5.0)5.0 (4.9)0.007TOAST classification, n (%)110 (40.4%)0.0070.013Small-artery atherosclerosis234 (47.1%)110 (40.4%)0.007Small-artery occlusion191 (38.4%)100 (36.8%)0.649Cardio-embolism53 (10.7%)46 (16.9%)0.623Other etiology15 (3.0%)10 (3.7%)6.623Other etiology15 (3.0%)10 (3.7%)6.623Platelet count, *10°/L (SD)193.6 (75.8)198.9 (65.7)0.354Serum UA, µmol/L (SD)32.1 (A.9)25.9 (7.9)0.808Serum Creatinine, µmol/L (SD)32.6 (32.8)65.2 (20.1)<0.001	Atrial fibrillation, n (%)	57 (11.5%)	47 (17.3%)	0.024					
Systolic blood pressure, mmHg (SD) 151.8 (23.7) 154.0 (24.4) 0.233 Diastolic blood pressure, mmHg (SD) 88.3 (16.1) 86.4 (14.5) 0.103 Admission NIHSS score, mean (SD) 4.6 (5.0) 5.0 (4.9) 0.404 TOAST classification, n (%) 101 (40.4%) 0.038 Large-artery atherosclerosis 234 (47.1%) 110 (40.4%) 0.017 Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 261 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Clinical features								
Protect in the interval	Time from onset to Admission, h (SD)	14.1 (8.5)	14.0 (8.5)	0.584					
Admission NIHSS score, mean (SD) 4.6 (5.0) 5.0 (4.9) 0.404 TOAST classification, n (%) 10 0.038 Large-artery atherosclerosis 234 (47.1%) 110 (40.4%) 0.077 Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001 RUI, mean (SD) 32.0 (8.2) 2.7 (0.8) <0.012 GFR, mL/min/1.73 m ² , (SD) 86.1 (21.0) 82.2 (19.4) 0.012 HbA1c, %, (SD) 68.8 (1.6) 6.8 (1.9) 0.556 LDL-C, µmol/L (SD) 86.1 (21.0) 3.0 (1.8) 0.148 Bradiological characteristics 3.0 (1.8) 0.124 0.523 Sponta	Systolic blood pressure, mmHg (SD)	151.8 (23.7)	154.0 (24.4)	0.233					
TOAST classification, n (%) Interface Interface 0.038 Large-artery atherosclerosis 234 (47.1%) 110 (40.4%) 0.077 Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Diastolic blood pressure, mmHg (SD)	88.3 (16.1)	86.4 (14.5)	0.103					
Large-artery atherosclerosis 234 (47.1%) 110 (40.4%) 0.077 Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 53 (10.7%) 46 (16.9%) 0.623 Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Admission NIHSS score, mean (SD)	4.6 (5.0)	5.0 (4.9)	0.404					
Small-artery occlusion 191 (38.4%) 100 (36.8%) 0.649 Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 0.53 (10.7%) 46 (16.9%) 0.623 Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	TOAST classification, n (%)			0.038					
Cardio-embolism 53 (10.7%) 46 (16.9%) 0.013 Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 53 (10.7%) 198.9 (65.7) 0.354 Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Large-artery atherosclerosis	234 (47.1%)	110 (40.4%)	0.077					
Undetermined etiology 15 (3.0%) 10 (3.7%) 0.623 Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index 5 5 5 Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, μmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Small-artery occlusion	191 (38.4%)	100 (36.8%)	0.649					
Other etiology 4 (0.8%) 6 (2.2%) 0.179 Laboratorial index - <t< td=""><td>Cardio-embolism</td><td>53 (10.7%)</td><td>46 (16.9%)</td><td>0.013</td></t<>	Cardio-embolism	53 (10.7%)	46 (16.9%)	0.013					
Laboratorial index Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Undetermined etiology	15 (3.0%)	10 (3.7%)	0.623					
Platelet count, *10 ⁹ /L (SD) 193.6 (75.8) 198.9 (65.7) 0.354 APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, µmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Other etiology	4 (0.8%)	6 (2.2%)	0.179					
APTT, s (SD) 26.1 (4.9) 25.9 (7.9) 0.808 Serum UA, μmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001	Laboratorial index								
Serum UA, μmol/L (SD) 362.8 (96.0) 304.8 (87.5) <0.001 RUI, mean (SD) 3.2 (0.8) 2.7 (0.8) <0.001	Platelet count, *10 ⁹ /L (SD)	193.6 (75.8)	198.9 (65.7)	0.354					
RUI, mean (SD) 3.2 (0.8) 2.7 (0.8) <0.001 Serum creatinine, µmol/L (SD) 82.6 (32.8) 65.2 (20.1) <0.001	APTT, s (SD)	26.1 (4.9)	25.9 (7.9)	0.808					
Serum creatinine, μmol/L (SD) 82.6 (32.8) 65.2 (20.1) <0.001 eGFR, mL/min/1.73 m², (SD) 86.1 (21.0) 82.2 (19.4) 0.012 HbA1c, %, (SD) 6.8 (1.6) 6.8 (1.9) 0.556 LDL-C, μmol/L (SD) 2.9 (1.1) 3.0 (1.8) 0.148 Radiological characteristics 5 5 5 5 Spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment 5 5 5 5 5 Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001	Serum UA, µmol/L (SD)	362.8 (96.0)	304.8 (87.5)	< 0.001					
eGFR, mL/min/1.73 m ² , (SD) 86.1 (21.0) 82.2 (19.4) 0.012 HbA1c, %, (SD) 6.8 (1.6) 6.8 (1.9) 0.556 LDL-C, µmol/L (SD) 2.9 (1.1) 3.0 (1.8) 0.148 Radiological characteristics Spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001 Antipypertensive, n (%) 272 (54.7%) 135 (49.6%) 0.176	RUI, mean (SD)	3.2 (0.8)	2.7 (0.8)	< 0.001					
HbA1c, %, (SD) 6.8 (1.6) 6.8 (1.9) 0.556 LDL-C, μmol/L (SD) 2.9 (1.1) 3.0 (1.8) 0.148 Radiological characteristics 5 5 5 5 Spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment 5 5 5 5 0.001 Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001	Serum creatinine, µmol/L (SD)	82.6 (32.8)	65.2 (20.1)	< 0.001					
LDL-C, μmol/L (SD) 2.9 (1.1) 3.0 (1.8) 0.148 Radiological characteristics 5 5 5 5 Spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 6 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment 5 5 5 5 5 Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 6 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001 Antihypertensive, n (%) 272 (54.7%) 135 (49.6%) 0.176	eGFR, mL/min/1.73 m ² , (SD)	86.1 (21.0)	82.2 (19.4)	0.012					
Radiological characteristics Image: spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment 500 (12.1%) 253 (93.0%) 0.001 Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001	HbA1c, %, (SD)	6.8 (1.6)	6.8 (1.9)	0.556					
Spontaneous HT, n (%) 18 (3.6%) 12 (4.4%) 0.589 Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment	LDL-C, µmol/L (SD)	2.9 (1.1)	3.0 (1.8)	0.148					
Large hemispheric infarction, n (%) 60 (12.1%) 25 (9.2%) 0.223 Treatment 486 (97.8%) 253 (93.0%) 0.001 Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001 Antihypertensive, n (%) 272 (54.7%) 135 (49.6%) 0.176	Radiological characteristics								
Treatment 486 (97.8%) 253 (93.0%) 0.001 Antiplatelet, n (%) 45 (9.1%) 49 (18.0%) <0.001	Spontaneous HT, n (%)	18 (3.6%)	12 (4.4%)	0.589					
Antiplatelet, n (%) 486 (97.8%) 253 (93.0%) 0.001 Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001	Large hemispheric infarction, <i>n</i> (%)	60 (12.1%)	25 (9.2%)	0.223					
Anticoagulant, n (%) 45 (9.1%) 49 (18.0%) <0.001 Antihypertensive, n (%) 272 (54.7%) 135 (49.6%) 0.176	Treatment								
Antihypertensive, n (%) 272 (54.7%) 135 (49.6%) 0.176	Antiplatelet, <i>n</i> (%)	486 (97.8%)	253 (93.0%)	0.001					
	Anticoagulant, <i>n</i> (%)	45 (9.1%)	49 (18.0%)	< 0.001					
Antidiabetic, n (%) 140 (28.2%) 72 (26.5%) 0.614	Antihypertensive, <i>n</i> (%)	272 (54.7%)	135 (49.6%)	0.176					
	Antidiabetic, <i>n</i> (%)	140 (28.2%)	72 (26.5%)	0.614					

HT, hemorrhagic transformation; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke; APTT, activated partial thromboplastin time; UA, uric acid; IQR, inter-quartile range; RUI, the ratio of UA and its IQR (RUI=UA/IQR); eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

Results

A total of 769 patients were finally included in this study (Figure 1), of whom 64.6% were male patients, with a mean age of (66.9 \pm 12.5) years and 30 (3.9%) had spontaneous HT. In this study, 70% of spontaneous HT was diagnosed by CT, 30% of spontaneous HT was diagnosed by MRI (T2WI and T1WI), 13.3% of patients with spontaneous HT performed SWI, and the result of SWI supports the diagnosis of CT/MRI. No patient with spontaneous HT was diagnosed by SWI alone. Among patients with spontaneous HT, one (3.3%) patient with PH2, seven (23.3%) patients with PH1, 13 (43.3%) patients with HI2, and nine (30.0%) patients with HI1 were identified. Compared with female patients, the male patients had a higher UA level (362.8 \pm 96.0 vs. 304.8 \pm 87.5, respectively; P < 0.001), RUI (3.2 \pm 0.8 vs. 2.7 \pm 0.8, respectively; P < 0.001), drinking, smoking, creatinine level, and eGFR and antiplatelet drug use rate. Female patients were older $(70.3 \pm 12.0 \text{ vs. } 65.0 \pm 12.4, \text{ respectively, } P < 0.001)$ and have higher occurrences of AF (17.3 vs. 11.5%, respectively, P = 0.024) and anticoagulant use than those of men (Table 1).

The male patients with spontaneous HT tended to have higher UA levels (428.3 \pm 124.5 vs. 360.3 \pm 94.0, respectively, P =0.003), RUI (3.7 \pm 1.1 vs. 3.1 \pm 0.8, respectively, P = 0.003), age, admission NIHSS score, higher occurrence of AF and LHI, and shorter time from the onset to admission compared to patients without. However, there was no significant association between UA/RUI and spontaneous HT in the female patients (P = 0.336) (Table 2).

After adjustment for factors with a $P < 0.05 \pmod{A}$ in the univariate analysis of each group by logistic regression, the ratio of UA/IQR was found to be independently associated with spontaneous HT in male patients (OR: 1.85; 95% CI: 1.07–3.19; P = 0.028), but not in female patients (OR: 1.39; 95% CI: 0.28– 6.82; P = 0.685). Furthermore, in the other three multivariate logistic regression models, the statistical results were consistent with model A after being adjusted for the factors with a P <0.05 in the univariate analyses of both subgroups (model B), anticoagulant use and antiplatelet drug (model C), and smoking, alcohol consumption, SBP, and eGFR (model D) (Figure 2).

Discussion

In this study, the RUI was independently associated with spontaneous HT in male patients admitted within 24 h after the onset, and the incidence of spontaneous HT increased by 85.0% for each IQR increase in the UA level. Interestingly, no similar association between the UA level and spontaneous HT was found in female patients.

Furthermore, we reported that UA levels were associated with spontaneous HT in male patients with acute ischemic stroke. However, this association was not found in female patients. UA levels are commonly available in medical settings, and the results of our study suggested that UA may be a potential target for interventions. Several previous studies have investigated the sex differences of UA in patients with cerebrovascular diseases (19, 20). Recently, a similar study reported that the incidence of spontaneous

TABLE 2 Univariate analysis to identify risk factors of spontaneous HT.

Variables		Male (<i>n</i> = 497)			Female (<i>n</i> = 272)		
	With HT	Without HT	P value	With HT	Without HT	P value	
Demographic							
Mean age, y (SD)	71.3 (13.8)	64.8 (12.3)	0.028	73.5 (14.5)	70.2 (11.9)	0.451	
Medical history							
Alcohol consumption, <i>n</i> (%)	10 (55.6%)	241 (50.3%)	0.662	0 (0.0%)	9 (3.5%)	1.000	
Smoking, <i>n</i> (%)	13 (72.2%)	340 (71.0%)	0.909	0 (0.0%)	13 (5.0%)	1.000	
Hypertension, <i>n</i> (%)	14 (77.8%)	347 (72.4%)	0.790	9 (75.0%)	190 (73.1%)	1.000	
Diabetes mellitus, <i>n</i> (%)	9 (50.0%)	143 (29.9%)	0.690	4 (33.3%)	79 (30.4%)	0.760	
Dyslipidemia, n (%)	6 (33.3%)	91 (19.0%)	0.136	2 (16.7%)	44 (16.9%)	1.000	
Atrial fibrillation, <i>n</i> (%)	6 (33.3%)	51 (10.6%)	0.011	8 (66.7%)	39 (15.0%)	< 0.001	
Clinical features							
Time from onset to admission, h (SD)	8.5 (8.0)	14.3 (8.5)	0.007	9.8 (9.2)	14.1 (8.4)	0.082	
Systolic blood pressure, mmHg (SD)	148.8 (22.5)	151.9 (23.8)	0.586	161.7 (29.9)	153.6 (24.1)	0.265	
Diastolic blood pressure, mmHg (SD)	83.9 (13.3)	88.5 (16.1)	0.236	85.9 (11.1)	86.4 (14.7)	0.901	
Admission NIHSS score, mean (SD)	11.8 (8.1)	4.4 (4.6)	0.001	10.3 (6.8)	4.7 (4.7)	0.015	
TOAST classification, n (%)			< 0.001			0.023	
Large-artery atherosclerosis	9 (50.0%)	225 (47.0%)	0.801	8 (66.7%)	102 (39.2%)	0.073	
Small-artery occlusion	0 (0.0%)	191 (39.9%)	0.001	0 (0.0%)	100 (38.5%)	0.005	
Cardio-embolism	7 (38.9%)	46 (9.6%)	0.001	4 (33.3%)	42 (16.2%)	0.126	
Undetermined etiology	2 (11.1%)	13 (2.7%)	0.098	0 (0.0%)	10 (3.8%)	1.000	
Other etiology	0 (0.0%)	4 (0.8%)	1.000	0 (0.0%)	6 (2.3%)	1.000	
Laboratorial index							
Platelet count, *10 ⁹ /L (SD)	179.7 (70.6)	194.2 (76.0)	0.438	178.5 (72.4)	199.8 (65.4)	0.294	
APTT, s (SD)	25.7 (3.5)	26.02 (4.9)	0.795	27.0 (5.2)	25.9 (8.0)	0.662	
Serum UA, µmol/L (SD)	428.3 (124.5)	360.3 (94.0)	0.003	328.6 (57.5)	303.7 (88.6)	0.336	
RUI, mean (SD)	3.7 (1.1)	3.1 (0.8)	0.003	2.9 (0.5)	2.7 (0.8)	0.336	
Serum creatinine, µmol/L(SD)	88.9 (36.6)	82.3 (32.7)	0.401	68.6 (16.6)	65.0 (20.9)	0.550	
eGFR, mL/min/1.73 m ² , (SD)	77.7 (25.7)	86.4 (20.8)	0.086	76.7 (18.6)	82.4 (19.4)	0.320	
HbA1c, %,(SD)	7.2 (2.3)	6.7 (1.6)	0.158	5.6 (2.1)	6,8 (1.9)	0.050	
LDL-C, µmol/L (SD)	2.7 (0.8)	2.9 (1.1)	0.597	3.1 (1.1)	3.0 (1.8)	0.860	
Radiological characteristics					·		
Large hemispheric infarction, <i>n</i> (%)	10 (55.6%)	50 (10.4%)	<0.001	9 (75%)	16 (6.2%)	< 0.001	
Treatment							
Antiplatelet, n (%)	18 (100%)	468 (97.7%)	1.000	10 (83.3%)	243 (93.5%)	0.201	
Anticoagulant, n (%)	4 (22.2%)	41 (8.6%)	0.700	1 (8.3%)	48 (18.5%)	0.700	
Antihypertensive, <i>n</i> (%)	8 (44.4%)	264 (55.1%)	0.372	4 (33.3%)	131 (50.4%)	0.248	
Antidiabetic, n (%)	8 (44.4%)	132 (27.6%)	0.118	4 (33.3%)	68 (26.2%)	0.524	

NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke; APTT, activated partial thromboplastin time; UA, uric acid; IQR, inter-quartile range; RUI, the ratio of UA and its IQR (RUI=UA/IQR); eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein cholesterol; SD, standard deviation.



FIGURE 2

The multivariate analysis to identify the association between RUI and spontaneous HT. Variables adjusted in logistic regression models: Model A. Factors with a P < 0.05 in male (or female) subgroup univariate analysis were included; model B: factors with a P < 0.05 in both subgroup univariate analysis were included; model C: variables in model B plus antiplatelet treatment and anticoagulant treatment; and model D: variables in model C plus smoking, alcohol consumption, systolic blood pressure, and eGFR.

HT was higher in patients with low UA levels than in patients with high UA levels (13). They included 1,230 patients who received reperfusion therapy within 7 days from the onset of the symptoms. However, in the context of our study, this finding was not confirmed. The reason for these contradictory results may partly be due to inclusion criteria. Moreover, it has been proven that the UA level of patients with stroke decreased gradually within 7 days after the onset, but there was no significant difference between the UA level measured 24 h after admission (15). This also may reflex the dual effect of UA. In a cross-sectional study of 2,686 patients, Jeong et al. reported that a high UA level was a risk factor for cerebral microbleeds only in male patients (19), and we confirmed and extended this finding in our study. Further studies are needed to explore whether these patients are potential candidates for interventions.

In previous studies, reperfusion treatment is one of the mechanisms of spontaneous HT, subsequently affecting the outcome. Previous studies regarding the relationship between UA and spontaneous HT have shown conflicting results in the thrombolysis population and non-thrombolysis group. Thrombectomy, the restoration of blood flow to the salvageable ischemic brain tissue, is consistent with the aforementioned mechanism of spontaneous HT, and a higher incidence of spontaneous HT was reported in previous studies. The reason for these contradictory results may partly be due to the modifying effect of reperfusion strategies on spontaneous HT in these studies. Thus, we excluded those patients from this study.

The exact underlying mechanism of UA levels on spontaneous HT remains unknown. Generally, UA is an abundant antioxidant in humans and is supposed to play a protective role in cardio-cerebral vascular diseases. The possible explanation of sex-dependent differences in UA levels on spontaneous HT was the uricosuric effect of estrogen (21), the inhibition of oxidative stress of blood vessels by estrogen (22), and the redox shuttle mechanism of UA (23). These three factors result in higher UA and lower antioxidant capacity in male patients than in female patients. In addition, UA is more effective in promoting oxidation in

an environment with relatively lower-antioxidative substances. Therefore, the stronger oxidation-promoting property of UA in male patients may be responsible for the sex difference in the occurrence of spontaneous HT. However, the opposite result has been found in many large-scale clinical studies (24-26). A literature review revealed that UA, which carries over half of the antioxidant capacity in plasma, may be involved in spontaneous HT through oxidative stress (4). This involvement can be partly explained by the following reasons: first, the production of UA by xanthine oxidase itself produces oxygen free radicals (27) and second, more oxygen free radicals will be produced after ischemia-reperfusion (5). UA has a redox shuttle effect in which the presentation of the antioxidant or pro-oxidant properties of UA depends on the surrounding environment. Specifically, antioxidant activity occurs when antioxidant substances are abundant, and prooxidant activity occurs if there are more pro-oxidants (23). In the environment of more oxygen free radicals in the ischemiareperfusion tissue, UA tends to be pro-oxidative. Therefore, UA may further aggravate oxidative stress and increase blood-brain barrier damage through the aforementioned mechanisms, which leads to spontaneous HT.

It should be noted that our study had some limitations. First, it was a single-center retrospective study with a relatively small sample size. The impact of UA on spontaneous HT seems to be limited in the sex-specific subgroups, and this clinical relevance may not be generalizable to patients with reperfusion treatment. In addition, a multicenter prospective study with a large sample size is required to further confirm and explore the association between UA and the subtypes of HT. Second, UA levels have been found to change over time in patients with stroke (15), whereas our study enrolled patients admitted to the hospital within 24 h after the stroke onset only. Hence, there will be a limited scope of application in terms of the findings in our study. In addition, our study retrospectively explained the association between the single UA level and spontaneous HT at admission, so it is still necessary to further clarify such a relationship by dynamical examination of the UA level in a prospective study.

Conclusion

In conclusion, among the non-reperfusion patients with acute ischemic stroke within 24 h after admission, the level of UA was independently and positively associated with the occurrence of spontaneous HT in male patients. More prospective research is needed to confirm these results.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Board of the First Affiliated Hospital of Chongqing Medical University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

YT and M-SL: study concept and design. YT, M-SL, and CF: acquisition of data. YT: statistical analysis and drafting of the manuscript. G-QL: critical revision of the manuscript for important intellectual content and study supervision. Analysis and interpretation of data were done by all authors. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. *Lancet Neurol.* (2013) 12:689–705. doi: 10.1016/S1474-4422(13)70055-3

2. Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. *Ann Transl Med.* (2014) 2:81. doi: 10.3978/j.issn.2305-5839.2014.08.08

3. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. *Arch Biochem Biophys.* (2000) 376:333–7. doi: 10.1006/abbi.2000.1721

4. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc Natl Acad Sci U S A*. (1981) 78:6858–62. doi: 10.1073/pnas.78.11.6858

5. Vassalle C, Mazzone A, Sabatino L, Carpeggiani C. Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hide? *Diseases*. (2016) 4:12. doi: 10.3390/diseases4010012

6. Chen Z, Chen H, Zhang Y, He Y, Su Y. Lower uric acid level may be associated with hemorrhagic transformation, but not functional outcomes in patients with anterior circulation acute ischemic stroke undergoing endovascular thrombectomy. *Metab Brain Dis.* (2020) 35:1157–64. doi: 10.1007/s11011-020-00601-7

7. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. *J Cereb Blood Flow Metab.* (2014) 34:185–99. doi: 10.1038/jcbfm.2013.203

 Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet.* (2004) 363:768– 74. doi: 10.1016/S0140-6736(04)15692-4

9. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet.* (2016) 387:1723–31. doi: 10.1016/S0140-6736(16)00163-X

10. Hao Y, Yang D, Wang H, Zi W, Zhang M, Geng Y, et al. Predictors for symptomatic intracranial hemorrhage after endovascular treatment of acute ischemic stroke. *Stroke*. (2017) 48:1203–9. doi: 10.1161/STROKEAHA.116.016368

11. Jovin TG, Li C, Wu L, Wu C, Chen J, Jiang C, et al. BAOCHE investigators. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. *N Engl J Med.* (2022) 387:1373–84. doi: 10.1056/NEJMoa2207576

12. Tao C, Nogueira RG, Zhu Y, Sun J, Han H, Yuan G, et al. ATTENTION investigators. Trial of endovascular treatment of acute basilar-artery occlusion. *N Engl J Med.* (2022) 387:1361–72. doi: 10.1056/NEJMoa2206317

13. Chen G, Wang A, Zhao X, Wang C, Liu L, Zheng H, et al. Frequency and risk factors of spontaneous hemorrhagic transformation following ischemic stroke on the initial brain CT or MRI: data from the China National Stroke Registry (CNSR). *Neurol Res.* (2016) 38:538–44. doi: 10.1080/01616412.2016. 1187864

14. Song Q, Wang Y, Cheng Y, Liu J, Wei C, Liu M. Serum uric acid and risk of hemorrhagic transformation in patients with acute ischemic stroke. *J Mol Neurosci.* (2020) 70:94–101. doi: 10.1007/s12031-019-01404-x

15. Brouns R, Wauters A, Van De Vijver G, De Surgeloose D, Sheorajpanday R, De Deyn PP. Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. *Clin Chem Lab Med.* (2010) 48:383–90. doi: 10.1515/CCLM.2010.065

16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF. 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* (2009) 150:604–12. doi: 10.7326/0003-4819-150-9-200905050-00006

17. Torbey MT, Bösel J, Rhoney DH, Rincon F, Staykov D, Amar AP, et al. Evidencebased guidelines for the management of large hemispheric infarction: a statement for health care professionals from the Neurocritical Care Society and the German Society for Neuro-intensive Care and Emergency Medicine. *Neurocrit Care.* (2015) 22:146–64. doi: 10.1007/s12028-014-0085-6

18. Kissela BM, Flaherty ML. Alwell K, Moomaw CJ, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III. *Trial Stroke.* (2012) 43:1591–5. doi: 10.1161/STROKEAHA.111.645986

19. Jeong SM, Yoo TG, Nam YS, Kim SH, Lee JE, Kim S, et al. Sex-dependent effects of uric acid on cerebral microbleed: a cross-sectional study in the general population. *Eur J Neurol.* (2017) 24:1300–6. doi: 10.1111/ene.13378

20. Chen LH, Zhong C, Xu T, Xu T, Peng Y, Wang A, et al. Sex-specific association between uric acid and outcomes after acute ischemic stroke: a prospective study from CATIS. *Trial Sci Rep.* (2016) 6:38351. doi: 10.1038/srep38351

21. Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. *Am J Physiol.* (1995) 268:E1–5. doi: 10.1152/ajpendo.1995.268.1.E1

22. Miller AA, De Silva TM, Jackman KA, Sobey CG. Effect of gender and sex hormones on vascular oxidative stress. *Clin Exp Pharmacol Physiol.* (2007) 34:1037–43. doi: 10.1111/j.1440-1681.2007.04732.x

23. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. *Nutr Metab (Lond).* (2004) 1:10. doi: 10.1186/1743-7075-1-10

24. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination Survey. *JAMA*. (2000) 283:2404–10. doi: 10.1001/jama.283. 18.2404

25. Gerber Y, Tanne D, Medalie JH, Goldbourt U. Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes. *Eur J Cardiovasc Prev Rehabil.* (2006) 13:193–8. doi: 10.1097/01.hjr.0000192745.269 73.00

26. Storhaug HM, Norvik JV, Toft I, Eriksen BO, Løchen ML, Zykova S, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. *BMC Cardiovasc Disord*. (2013) 13:115. doi: 10.1186/1471-2261-13-115

27. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. *Proc Natl Acad Sci U S A*. (1988) 85:4046–50. doi: 10.1073/pnas.85.11.4046